粒径
差示扫描量热法
格列本脲
生物利用度
溶解度
溶解
材料科学
纳米颗粒
Zeta电位
聚合物
溶剂
化学工程
化学
核化学
纳米技术
有机化学
药理学
复合材料
糖尿病
物理
工程类
内分泌学
热力学
医学
作者
Chander Parkash Dora,Shailendra Kumar Singh,Sanjeev Kumar,Ashok Kumar Datusalia,Aakash Deep
出处
期刊:PubMed
日期:2010-06-09
卷期号:67 (3): 283-90
被引量:36
摘要
The aim of this study was to formulate nanoparticles (NPs) containing glibenclamide (GB) prepared with Eudragit L100 to achieve a better release profile suitable for per oral administration with enhanced efficacy. The NPs were prepared by solvent displacement method. The influence of various formulation factors (drug : polymer ratio and concentration of surfactants) on particle size, size distribution, zeta potential, drug loading and encapsulation efficiency were investigated. Drug : polymer ratio was observed to be important parameter influencing mean particle size, beside others. Encapsulation efficiency and drug loading capacity were found to be increased as drug concentration increases with respect to polymer. Addition of surfactants showed a promising result in decreasing particle size of NPs. Dissolution study revealed increased release of GB from NPs. Transmission electron microscopy (TEM) study revealed spherical morphology of the developed NPs. Differential scanning calorimetry (DSC) studies confirmed phase transition behavior of NPs. They also showed very significant change in saturation solubility in comparison with pure drug. Developed NPs revealed a decreased t(min) and enhanced bioavailability and hence superior activity as compared to plain GB in alloxan-induced diabetic rabbit model. The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance.
科研通智能强力驱动
Strongly Powered by AbleSci AI